Literature DB >> 1310755

Protection against Marek's disease by a fowlpox virus recombinant expressing the glycoprotein B of Marek's disease virus.

K Nazerian1, L F Lee, N Yanagida, R Ogawa.   

Abstract

Fowlpox virus (FPV) recombinants expressing the glycoprotein B and the phosphorylated protein (pp38) of the GA strain of Marek's disease virus (MDV) were assayed for their ability to protect chickens against challenge with virulent MDV. The recombinant FPV expressing the glycoprotein B gene elicited neutralizing antibodies against MDV, significantly reduced the level of cell-associated viremia, and, similar to the conventional herpesvirus of turkeys, protected chickens against challenge with the GA strain and the highly virulent RB1B and Md5 strains of MDV. The recombinant FPV expressing the pp38 gene failed to either elicit neutralizing antibodies against MDV or protect the vaccinated chickens against challenge with MDV.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1310755      PMCID: PMC240864     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  21 in total

1.  Mechanisms of antiviral immunity induced by a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: cytotoxic T cells.

Authors:  S Martin; B Moss; P W Berman; L A Laskey; B T Rouse
Journal:  J Virol       Date:  1987-03       Impact factor: 5.103

2.  Marek's disease virus gene clones encoding virus-specific phosphorylated polypeptides and serological characterization of fusion proteins.

Authors:  Z Z Cui; D Yan; L F Lee
Journal:  Virus Genes       Date:  1990-04       Impact factor: 2.332

3.  Coexpression by vaccinia virus recombinants of equine herpesvirus 1 glycoproteins gp13 and gp14 results in potentiated immunity.

Authors:  P X Guo; S Goebel; M E Perkus; J Taylor; E Norton; G Allen; B Languet; P Desmettre; E Paoletti
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

4.  Studies on glycoprotein 13 (gp13) of equid herpesvirus 1 using affinity-purified gp13, glycoprotein-specific monoclonal antibodies and synthetic peptides in a hamster model.

Authors:  A Stokes; A H Corteyn; L A Pullen; T R Doel; D M Meredith; R A Killington; I W Halliburton; G R Whittaker; L A Wheldon; L Nicolson
Journal:  J Gen Virol       Date:  1991-04       Impact factor: 3.891

5.  DNA sequence and organization of genes in a 5.5 kbp EcoRI fragment mapping in the short unique segment of Marek's disease virus (strain RB1B).

Authors:  L J Ross; M M Binns; J Pastorek
Journal:  J Gen Virol       Date:  1991-04       Impact factor: 3.891

6.  Structural analysis and transcriptional mapping of the Marek's disease virus gene encoding pp38, an antigen associated with transformed cells.

Authors:  Z Z Cui; L F Lee; J L Liu; H J Kung
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

7.  Expression of herpes simplex virus 1 glycoprotein B by a recombinant vaccinia virus and protection of mice against lethal herpes simplex virus 1 infection.

Authors:  E M Cantin; R Eberle; J L Baldick; B Moss; D E Willey; A L Notkins; H Openshaw
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

8.  Detection of antibodies to herpes simplex virus with a continuous cell line expressing cloned glycoprotein D.

Authors:  P W Berman; D Dowbenko; L A Lasky; C C Simonsen
Journal:  Science       Date:  1983-11-04       Impact factor: 47.728

9.  Recombinant fowlpox viruses expressing the glycoprotein B homolog and the pp38 gene of Marek's disease virus.

Authors:  N Yanagida; R Ogawa; Y Li; L F Lee; K Nazerian
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

10.  Characterization of an apparently nononcogenic Marek's disease virus.

Authors:  K A Schat; B W Calnek
Journal:  J Natl Cancer Inst       Date:  1978-05       Impact factor: 13.506

View more
  18 in total

1.  Development of an effective polyvalent vaccine against both Marek's and Newcastle diseases based on recombinant Marek's disease virus type 1 in commercial chickens with maternal antibodies.

Authors:  K Sonoda; M Sakaguchi; H Okamura; K Yokogawa; E Tokunaga; S Tokiyoshi; Y Kawaguchi; K Hirai
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

Review 2.  Non-replicating expression vectors: applications in vaccine development and gene therapy.

Authors:  K J Limbach; E Paoletti
Journal:  Epidemiol Infect       Date:  1996-06       Impact factor: 2.451

3.  Expression of cytokine genes in Marek's disease virus-infected chickens and chicken embryo fibroblast cultures.

Authors:  Z Xing; K A Schat
Journal:  Immunology       Date:  2000-05       Impact factor: 7.397

4.  Open reading frames in a 4556 nucleotide sequence within MDV-1 BamHI-D DNA fragment: evidence for splicing of mRNA from a new viral glycoprotein gene.

Authors:  Y Becker; Y Asher; E Tabor; I Davidson; M Malkinson
Journal:  Virus Genes       Date:  1994-01       Impact factor: 2.332

5.  Selective induction of immune responses by cytokines coexpressed in recombinant fowlpox virus.

Authors:  K H Leong; A J Ramsay; D B Boyle; I A Ramshaw
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

6.  Characterization of a recombinant fowlpox virus expressing the native hexon of hemorrhagic enteritis virus.

Authors:  C J Cardona; K Nazerian; W M Reed; R F Silva
Journal:  Virus Genes       Date:  2001-06       Impact factor: 2.332

Review 7.  The Leeuwenhoek Lecture, 1997. Marek's disease herpesvirus: oncogenesis and prevention.

Authors:  P M Biggs
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1997-12-29       Impact factor: 6.237

8.  Role of the TK+ phenotype in the stability of pigeonpox virus recombinant.

Authors:  C Letellier
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

9.  Infectious bursal disease virus structural protein VP2 expressed by a fowlpox virus recombinant confers protection against disease in chickens.

Authors:  H G Heine; D B Boyle
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

10.  Fowlpox virus recombinants expressing the envelope glycoprotein of an avian reticuloendotheliosis retrovirus induce neutralizing antibodies and reduce viremia in chickens.

Authors:  J G Calvert; K Nazerian; R L Witter; N Yanagida
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.